Antiviral Trial Shows Reduced COVID-19 Transmission

Japan-based company Shionogi & Co. announced Wednesday (Oct. 29) that its Phase 3 trial for ensitrelvir showed the drug reduced the chances of a person catching COVID-19 from a household member infected with the virus. The drug, undergoing fast-track review by FDA, if approved could become the first COVID-19 oral antiviral available for post-exposure prophylactic use. “COVID-19 remains an important public health priority, yet there are currently no oral antiviral medications approved for post-exposure prophylactic use,” Simon Portsmouth, head of...